Clinical Trial Update: Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cannabidiol in people with multiple sclerosis, exploring how sleep and pain phenotype influence outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Tiffany J. Braley, MD, MS | Conditions: Multiple Sclerosis, Sleep | Phase 2 | Status: RECRUITING